U.S. Stock News

NasdaqGS:ACLX
NasdaqGS:ACLXBiotechs

Assessing Arcellx (ACLX) Valuation After New Preclinical Data On BCMA CAR T Therapy Anito Cel

Arcellx (ACLX) shares are in focus after the company reported late breaking preclinical data on its BCMA directed CAR T therapy anitocabtagene autoleucel, highlighting its compact D Domain binder and potential safety differentiation. See our latest analysis for Arcellx. At a share price of $68.50, Arcellx has seen a 90 day share price return decline of 23.88%, while its year to date share price return of 8.15% and three year total shareholder return of 135.40% point to longer term momentum...
NYSE:STC
NYSE:STCInsurance

A Look At Stewart Information Services (STC) Valuation As Recent Returns Cool From Three Year Gains

Stewart Information Services (STC) has been drawing attention after recent share price moves, with the stock showing mixed short term returns that contrast with its longer term performance profile and underlying business scale. See our latest analysis for Stewart Information Services. At a share price of US$69.39, Stewart Information Services has seen a 5.1% 30 day share price return, while its 1 year total shareholder return of 4.3% compares with a much stronger 3 year total shareholder...
NYSE:PRU
NYSE:PRUInsurance

A Look At Prudential Financial (PRU) Valuation After Strong Results Insider Buying And Dividend Update

Prudential Financial (PRU) is back in focus after reporting fourth quarter net income of US$905 million and full year net income of US$3.58b, alongside insider share purchases and a declared US$1.40 quarterly dividend. See our latest analysis for Prudential Financial. At a share price of US$104.61, Prudential Financial has seen a 2.36% 7 day share price return but a 6.34% 30 day share price decline. Its 5 year total shareholder return of 52.45% contrasts with a slightly negative 1 year total...
NYSE:HCI
NYSE:HCIInsurance

Earnings Breakout and Discount Valuation Could Be A Game Changer For HCI Group (HCI)

Recently, HCI Group reported quarterly earnings per share of US$4.90, up from US$0.47 a year earlier, and has exceeded consensus EPS forecasts in each of the past four quarters while carrying an A-grade valuation score versus peers. This combination of very strong earnings growth, consistent estimate beats, and a discount valuation has brought fresh attention to HCI Group’s operating performance and positioning within property and casualty insurance. We’ll now examine how HCI Group’s recent...
NasdaqCM:ATOM
NasdaqCM:ATOMSemiconductor

Is Atomera’s (ATOM) MST Progress With Gate-All-Around Tech Reframing Its Core Investment Story?

In February 2026, Atomera Incorporated reported fourth-quarter 2025 sales of US$50,000 with a net loss of US$4.43 million, and full-year 2025 sales of US$65,000 with a net loss of US$20.17 million, alongside updated Delaware law-aligned bylaws. Alongside these results, Atomera highlighted progress integrating its MST technology into advanced Gate-All-Around transistor structures and GaN-on-silicon applications, supported by a new major equipment OEM partnership and collaborations with...
NYSE:TRGP
NYSE:TRGPOil and Gas

Assessing Targa Resources (TRGP) Valuation After Record EBITDA, Raised Outlook And Expansion Plans

Targa Resources (TRGP) is back in focus after reporting record adjusted EBITDA of US$1.27b in Q3 2025, issuing a higher full-year outlook, advancing major Permian growth projects, and outlining plans for a higher dividend. See our latest analysis for Targa Resources. The recent Q3 earnings beat, higher outlook and new Permian projects have coincided with a 20.8% 1 month share price return and a 32.0% 3 month share price return. The 3 year total shareholder return of more than 3x suggests...
NasdaqGS:ENSG
NasdaqGS:ENSGHealthcare

Ensign Group (ENSG) Is Up 7.0% After Raising 2026 Guidance And Expanding Facility Footprint

The Ensign Group reported past fourth-quarter and full-year 2025 results showing higher revenue and earnings, issued 2026 earnings guidance of US$7.41 to US$7.61 per diluted share and revenue guidance of US$5.77 billion to US$5.84 billion, and disclosed no share repurchases under its existing buyback authorization. Alongside this guidance, Ensign expanded its footprint to 378 healthcare operations across 17 states through several skilled nursing facility acquisitions, underscoring...